​

GeneDx (WGS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

WGS Stock Forecast

GeneDx (WGS) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $87.43, with a high of $150.00 and a low of $63.00. This represents a 44.42% increase from the last price of $60.54.

- $30 $60 $90 $120 $150 High: $150 Avg: $87.43 Low: $63 Last Closed Price: $60.54

WGS Stock Rating

GeneDx stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (90.91%), 1 Hold (9.09%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 1 10 Strong Sell Sell Hold Buy Strong Buy

WGS Price Target Upside V Benchmarks

TypeNameUpside
StockGeneDx44.42%
SectorHealthcare Stocks 15.45%
IndustryHealthcare Information Services Stocks 21.08%

Price Target Trends

1M3M12M
# Anlaysts1719
Avg Price Target$74.00$76.00$125.11
Last Closing Price$60.54$60.54$60.54
Upside/Downside22.23%25.54%106.66%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 2618---9
Jun, 2618---9
May, 2618---9
Apr, 2618---9
Mar, 2618---9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 29, 2026Guggenheim$74.00$69.825.99%22.23%
Jun 23, 2026David WestenbergPiper Sandler$63.00$55.4213.68%4.06%
May 05, 2026Bill BonelloCraig-Hallum$85.00$35.59138.83%40.40%
May 05, 2026BTIG$90.00$67.9332.49%48.66%
May 05, 2026Guggenheim$70.00$67.933.05%15.63%
May 05, 2026Kyle MiksonCanaccord Genuity$75.00$67.9310.41%23.89%
May 05, 2026Brandon CouillardWells Fargo$75.00$67.9310.41%23.89%
Apr 20, 2026Canaccord Genuity$100.00$67.7247.67%65.18%
Feb 24, 2026Mark MassaroBTIG$170.00$87.0895.22%180.81%
Feb 24, 2026David WestenbergPiper Sandler$130.00$87.0849.29%114.73%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jul 15, 2026Cowen & Co.BuyBuyhold
Jun 29, 2026GuggenheimBuyBuyhold
Jun 23, 2026Piper SandlerOverweightOverweighthold
May 05, 2026Craig-HallumBuyBuyhold
May 05, 2026Wells FargoOverweightOverweighthold
Feb 24, 2026BTIGBuyBuyhold
Feb 24, 2026Piper SandlerOverweightOverweighthold
Feb 09, 2026Wells FargoEqual-WeightOverweightupgrade
Dec 12, 2025BTIGBuyBuyhold
Oct 29, 2025BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-75 $-59 $-43 $-27 $-11 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-74.93$-53.63$-7.23$-1.94$-0.73--
Avg Forecast$-34.54$-29.04$-5.35$-0.27$0.55$1.46$2.68
High Forecast$-34.00$-28.74$-5.26$-0.26$0.56$2.17$2.75
Low Forecast$-35.31$-29.45$-5.49$-0.27$0.54$0.74$2.63
Surprise %116.94%84.68%35.14%618.52%-232.73%--

Revenue Forecast

$150M $220M $290M $360M $430M $500M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$212.19M$234.69M$202.57M$305.45M$427.54M--
Avg Forecast$203.77M$244.28M$192.76M$290.22M$338.77M$398.42M$476.30M
High Forecast$207.25M$246.90M$196.45M$295.78M$345.27M$406.06M$485.43M
Low Forecast$201.34M$242.35M$190.23M$286.41M$334.33M$393.20M$470.05M
Surprise %4.14%-3.92%5.09%5.25%26.20%--

Net Income Forecast

$-900M $-700M $-500M $-300M $-100M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$-245.39M$-548.98M$-175.77M$-52.29M$-21.02M--
Avg Forecast$-839.74M$-706.04M$-130.66M$-6.47M$13.36M$35.41M$65.16M
High Forecast$-826.71M$-698.78M$-127.93M$-6.33M$13.64M$52.75M$66.78M
Low Forecast$-858.41M$-715.90M$-133.39M$-6.60M$13.08M$18.08M$64.05M
Surprise %-70.78%-22.25%34.52%708.38%-257.31%--

WGS Forecast FAQ

Is GeneDx stock a buy?

GeneDx stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that GeneDx is a favorable investment for most analysts.

What is GeneDx's price target?

GeneDx's price target, set by 11 Wall Street analysts, averages $87.43 over the next 12 months. The price target range spans from $63 at the low end to $150 at the high end, suggesting a potential 44.42% change from the previous closing price of $60.54.

How does GeneDx stock forecast compare to its benchmarks?

GeneDx's stock forecast shows a 44.42% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the healthcare information services stocks industry (21.08%).

What is the breakdown of analyst ratings for GeneDx over the past three months?

  • July 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 11.11% Strong Buy, 88.89% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is GeneDx’s EPS forecast?

GeneDx's average annual EPS forecast for its fiscal year ending in December 2026 is $1.46, marking a -300.00% decrease from the reported $-0.73 in 2025. Estimates for the following years are.

What is GeneDx’s revenue forecast?

GeneDx's average annual revenue forecast for its fiscal year ending in December 2026 is $398.42M, reflecting a -6.81% decrease from the reported $427.54M in 2025. The forecast for.

What is GeneDx’s net income forecast?

GeneDx's net income forecast for the fiscal year ending in December 2026 stands at $35.41M, representing a -268.47% decrease from the reported $-21.021M in 2025. Projections indicate .